Dipna Pharmachem
DIPNAPHARMACHEMLTD NSE
Dipna Pharmachem
HealthcareNSE: DIPNAPHARMACHEMLTD BSE: 543594 Pharmaceuticals
Key Fundamentals
SMEPharmaceuticalsHealthcareMarket Cap
₹12.20 Cr
Volatility
Moderate
P/E Ratio
4.7
EBITDA
₹4.99 Cr
Return on Equity
2.53%
Debt to Equity
0.21
Book Value
₹23.7
EPS
₹0.45
52W High
₹25
52W Low
₹3.9
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Stock is trading at 0.19 times its book value
- Company's working capital requirements have reduced from 91.1 days to 55.6 days
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 9.13%
- Company has a low return on equity of 3.93% over last 3 years.
- Promoter holding has decreased over last 3 years: -57.4%
Growth Rate
Revenue Growth
3.35% lower than
3Y
Net Income Growth
162% higher than
3Y
Cash Flow Change
-69.56% lower than
3Y
ROE
-12.46% lower than
3Y
ROCE
6.3% lower than
3Y
EBITDA Margin (Avg.)
40.22% lower than
3Y
Quarterly Results
| Particulars | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 15.92 | 53.52 | 2.05 |
| Expenses | 14.64 | 51.87 | 1.59 |
| Operating Profit | 1.28 | 1.65 | 0.46 |
| OPM % | 8.04% | 3.08% | 22.44% |
| Other Income | 0 | 0 | 0 |
| Interest | 0.6 | 0.23 | 0.23 |
| Depreciation | 0 | 0 | 0 |
| PBT | 0.68 | 1.42 | 0.23 |
| Tax % | 26.47% | 26.06% | 21.74% |
| Net Profit | 0.5 | 1.04 | 0.18 |
| EPS in Rs | 0.21 | 0.4 | 0.07 |
Profit & Loss
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 20 | 30 | 31 | 73 | 100 | 164 | 125 | 129 |
| Expenses | 16 | 20 | 30 | 31 | 71 | 98 | 161 | 121 | 124 |
| Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 5 |
| OPM % | 2.4% | 2.4% | 1.5% | 1.3% | 3% | 2.4% | 2.1% | 3% | 3.9% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| PBT | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 4 |
| Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | 32% | 26% |
| Net Profit | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 3 |
| EPS in Rs | 6 | 3 | 6 | 2 | 117 | 0.37 | 0.45 | 0.4 | 1 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 | 26 |
| Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 | 36 |
| Borrowings | 5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | 13 |
| Other Liabilities | 6 | 8 | 8 | 12 | 24 | 37 | 76 | 77 | 130 |
| Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
| Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 132 | 206 |
Cash Flow
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating | — | — | -3 | -2 | 3 | -21 | -5 | -9 | -18 |
| Investing | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing | — | — | 3 | 2 | -3 | 26 | 14 | -4 | 19 |
| Net Cash Flow | — | — | 0 | 0 | 0 | 5 | 8 | -13 | 0 |
| Free Cash Flow | — | — | -3 | -2 | 3 | -21 | -5 | -9 | -18 |
| CFO/OP | — | — | -693 | -618 | 148 | -893 | -157 | -246 | -347 |
Ratios
| Particulars | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 | 135 | 136 |
| Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 | 88 | 144 |
| Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 | 243 | 375 |
| Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 | -20 | -95 |
| Working Capital Days | 3 | 6 | 44 | 47 | 37 | 108 | 80 | 137 | 56 |
| ROCE % | — | 8% | 5% | 3% | 17% | 9% | 7% | 7% | 8% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Dipna Pharmachem insights
61 extracted metrics + investor summaries across FY13–FY26.
Documents
2
Board Meeting Outcome for Outcome Of The Board Meeting And Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
22 Apr - Board recommended secretarial auditor appointment for FY2025-26; postal ballot e-voting runs 23 Apr-22 May 2026. 22 Apr - Board recommended secretarial auditor appointment for FY2025-26; postal ballot e-voting runs 23 Apr-22 May 2026.
3
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
22 Apr - Board approved secretarial auditor appointment for FY2025-26 and postal ballot e-voting from 23 April to 22 May 2026. 22 Apr - Board approved secretarial auditor appointment for FY2025-26 and postal ballot e-voting from 23 April to 22 May 2026.
4
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
22 Apr - Postal ballot issued for appointing M/s. Jay Pandya & Associates as secretarial auditor for FY2025-26. 22 Apr - Postal ballot issued for appointing M/s. Jay Pandya & Associates as secretarial auditor for FY2025-26.
5
Board Meeting Outcome for Outcome Of The Board Meeting And Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
22 Apr - Board recommended secretarial auditor appointment for FY2025-26; postal ballot e-voting runs 23 Apr-22 May 2026. 22 Apr - Board recommended secretarial auditor appointment for FY2025-26; postal ballot e-voting runs 23 Apr-22 May 2026.
Frequently Asked Questions about Dipna Pharmachem
What does Dipna Pharmachem Ltd do?
Incorporated in 2011, Dipna Pharmachem Ltd
is in the business of Pharmaceutical Trading[1]
Where is Dipna Pharmachem Ltd (543594) listed?
Dipna Pharmachem Ltd trades as DIPNAPHARMACHEMLTD on the NSE and under code 543594 on the BSE.
Which sector does Dipna Pharmachem Ltd belong to?
Dipna Pharmachem Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd has a market capitalisation of ₹12.2 Cr, which places it in the Small Cap band.
What is the PE ratio of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd trades at a PE ratio of 4.70, on earnings per share of ₹0.45, against a book value of ₹23.7 per share.
What is the 52-week high and low of Dipna Pharmachem Ltd?
Over the last 52 weeks Dipna Pharmachem Ltd has traded between ₹3.9 and ₹25.
What is the Return on Equity (ROE) of Dipna Pharmachem Ltd?
Dipna Pharmachem Ltd reported a return on equity of 2.53%. Its debt-to-equity ratio is 0.21.
Company Information
Incorporated in 2011, Dipna Pharmachem Ltd is in the business of Pharmaceutical Trading[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543594.md for Dipna Pharmachem Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.